The goal of this project is to develop a lateral flow assay for detecting complement levels and complement activation status in a patient. This assay will give results in seconds versus either hours or days that normal complement lab assays have. It also will give more accurate results than conventional assays. The complement system is a group of more than 30 serum and membrane proteins that comprise an important effector arm of the innate immune system. However, complement can also damage host tissue, leading to its being termed a "double-edged sword." Complement plays a role in many, and diverse, diseases such as age- related macular degeneration (AMD), arthritis, stroke, trauma, and more. Altogether more than 30 million Americans suffer from complement-involved disorders. One problem facing detecting and treating these diseases are fast and reliable assays. For some indications such as trauma massive complement activation can occur within minutes of injury. This often proceeds a cytokine storm that can cause shock or organ failure. Knowing the cytokine storm is imminent allows preemptive treatment. In other cases the samples must be shipped for complement is very labile and does not store well at temperatures warmer than -80C. A lateral flow assay will allow immediate accurate results that are not available to most labs at present.
Public Health Relevance: We intend to develop a point of care, lateral flow assay for the detection and quantification of complement component 3 and its metabolites. This is to address the variability of other assay formats caused by the duration of the assay, and the test article handling and storage.
Thesaurus Terms: Address; Age Related Macular Degeneration; American; Apoplexy; Area; Arm; Arthritis; Assay; Award; Bedside Testings; Bioassay; Biologic Assays; Biological Assay; Blood; Blood Serum; Body Tissues; Businesses; Cerebral Stroke; Cerebrovascular Apoplexy; Cerebrovascular Stroke; Cerebrovascular Accident; Circulatory Collapse; Clinic; Clinical; Clinical Trials; Clinical Trials, Unspecified; Complement; Complement 3; Complement Activation; Complement Component 3; Complement Proteins; Detection; Development; Diagnosis; Disease; Disorder; Elisa; Enzyme-Linked Immunosorbent Assay; Equipment; Goals; Hour; Human; Human, General; Immune System; Immunoassay; Injury; Lateral; Maculopathy, Age-Related; Man (Taxonomy); Man, Modern; Marketing; Mediating; Membrane Proteins; Membrane-Associated Proteins; Organ Failure; Patients; Pharmaceutical Agent; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Play; Process; Reader; Reagent; Recovery; Research; Reticuloendothelial System, Blood; Role; Running; Sampling; Serologic; Serologic Tests; Serological; Serological Tests; Serum; Shipping; Ships; Shock; Site; Stroke; Surface Proteins; Technology; Testing; Testings, Bedside; Time; Tissues; Trauma; Upper Arm; Validation; Vascular Accident, Brain; Arthritic; Base; Body System, Allergic/Immunologic; Brain Attack; Catalyst; Cerebral Vascular Accident; Circulatory Shock; Clinical Investigation; Complement Pathway Regulation; Complement System; Cost; Cost Effective; Cytokine; Disease/Disorder; Drug Development; Innovate; Innovation; Innovative; Organ System, Allergic/Immunologic; Point Of Care; Point Of Care Testing; Public Health Relevance; Senile Macular Disease; Serology; Social Role; Stroke; Warm Temperature
